Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
M.D. Anderson Cancer Center
Deoxycoformycin(DCF)/Pentostatin is a T-cell cytotoxic drug with previously reported responses in lymphoid malignancies but larger studies are needed.
Age
16–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Histologic proof of lymphoid malignancy with an expected complete response rate of less than 20 percent OR have failed at least one prior therapy.
No chemotherapy within 3 weeks of entry into study and must have recovered from acute toxic effects of prior therapy.
Life expectancy of at least 12 weeks.
Performance status equal to or less than Zubrod 2.
Signed informed consent.
Patients with measurable disease.
Age at least 16 years.
Adequate bone marrow function (unless involvement of bone marrow by lymphoma) defined as AGC greater than 1500 and platelet count greater than 100,000.
Adequate hepatic function with a bilirubin less than or equal to 1.5 mg % and SGPT less than or equal to 4 times the upper limits of normal.
Adequate renal function defined as serum creatine less than or equal to 1.5 mg %.
You may not be if
No serious intercurrent illness.
Adequate contraception (if applicable).
NO patients with significant cardiac disease, i.e. New York Heart Association (NYHA) class III or IV.
NO experimental clinical trial within 3 weeks of study entry.
NO patients with active CNS disease.
Full recovery from any prior surgical treatment.
NO active active infections.
Clareo Health | A Study Of Deoxycoformycin(DCF)/Pentostatin In Lymphoid Malignancies
